Novo Nordisk i aso nei ua faʻasalalau e le US Food and Drug Administration (FDA) ua faʻamaonia le 2 mg dose o le Ozempic® (semaglutide) tui, o se glucagon-like peptide-1 (GLP-1) faʻatasi i vaiaso taʻitasi faʻatasi ma meaʻai ma faamalositino. e faʻaleleia ai le suka toto i tagata matutua e maua i le maʻisuka ituaiga 2 ma faʻaitiitia le lamatiaga o faʻalavelave faʻafuaseʻi o le cardiovascular e pei o le fatu fatu, stroke poʻo le oti i tagata matutua e maua i le maʻisuka ituaiga 2 ma le maʻi fatu ua iloa.2 Ozempic® e le o se vailaʻau paʻu mamafa, ae atonu fesoasoani i tagata e fa'aitiitia sina mamafa. Ozempic® o le a maua i tui e tolu (0.5 mg, 1 mg, ma le 2 mg) e fesoasoani ai i tagata e maua i le ma'isuka ituaiga 2 e ausia a latou sini o le suka toto (A1C), lea e aofia ai i latou e maualuga atu le A1C ua le mafai ona ausia a latou sini. A1C sini.
I le Ozempic® SUSTAIN phase 3 clinical trial program, e oʻo atu i le 73% o tagata e maua i le maʻisuka ituaiga 2 na togafitia i le Ozempic® 1 mg na faʻaititia a latou suka toto ma ausia le sini a le American Diabetes Association e <7%.3-5 E ui lava i lea, o loʻo i ai. o lo'o i ai pea tagata e le o iai i le latou toto suka.1,4-10 Ozempic® 2 mg fesoasoani ia i latou o lo'o mana'omia le fa'aopoopoina o le glycemic control ma o se filifiliga taua mo gasegase ma tagata e tu'uina atu i le togafitiga faifaipea o le ma'isuka ituaiga 2.
"O le maʻisuka ituaiga 2 o se faʻamaʻi lavelave e mafai ona alualu i luma i le taimi e tusa lava pe o loʻo pulea e se tagata i vailaʻau, meaʻai ma faʻamalositino," o le tala lea a Dr Juan Pablo Frias, faʻatonu fomaʻi o Velocity Clinical Research, Los Angeles ma le suʻesuʻega autu a SUSTAIN FORTE, le vaega 3 faʻataʻitaʻiga faʻataʻitaʻiga e lagolagoina le faʻatagaina o le Ozempic® 2 mg. "Faatasi ai ma lona saogalemu ma le aoga, o le Ozempic® e fesoasoani i le faʻatonutonuina o le kulukose toto ma ofoina atu le faʻaitiitia o le lamatiaga o le cardiovascular i tagata matutua e maua i le maʻisuka ituaiga 2 ma faʻamaʻi fatu, ma e mafai ona fesoasoani i le tele o gasegase e faʻaitiitia ai le mamafa. Faatasi ai ma le 2 mg dose, e iai la matou filifiliga faaopoopo ina ia mafai ai e tagata gasegase ona tumau i le togafitiga tutusa e tusa lava pe manaʻomia le suiga o latou suka toto.
I le suʻesuʻega a le SUSTAIN FORTE, o tagata o loʻo i ai le averesi amata A1C o le 8.9% na togafitia i le Ozempic® 2 mg na ausia se faʻaitiitiga taua ma sili atu le faʻaitiitia o le suka toto o le 2.1% i le vaiaso 40 faʻatusatusa i le 1.9% ma le Ozempic® 1 mg (P<0.01). ).1 I le suʻesuʻega lava e tasi, o tagata o loʻo i ai le mamafa amata o le 219 lb na togafitia i le Ozempic® 2 mg na maua le mamafa o le 14.1 lb pe a faʻatusatusa i le mamafa o le 12.5 lb ma le Ozempic® 1 mg; e le'i taua tele le eseesega. Mo tui uma e lua o le Ozempic®, e leai ni faʻailoga fou o le saogalemu na faʻaalia.1 O faʻalavelave sili ona taatele o le gastrointestinal.1 Gastrointestinal faʻalavelave faʻafuaseʻi na tupu soo i tagata mamaʻi e mauaina Ozempic® 2 mg (34.0%) vs Ozempic® 1 mg (30.8% ).1
"O le Ozempic® o loʻo i le foʻi o le fesoasoani ia Novo Nordisk e faʻatautaia suiga i le tausiga o le maʻisuka, ma e sili atu ma le tasi miliona tagata e maua i le maʻisuka ituaiga 2 i le Iunaite Setete o loʻo togafitia i le Ozempic®," o le tala lea a Doug Langa, sui peresitene pule, faʻagaioiga ma peresitene o Amerika i Matu. o le Novo Nordisk Inc. "Faatasi ai ma le Ozempic® o loʻo avanoa nei i le tele o malosi faʻamaʻi, matou te faʻamoemoe e mafai ona matou fesoasoani i le tele o tagata o loʻo maua i le maʻisuka ituaiga 2 o loʻo manaʻomia le tele o le puleaina o le suka toto e iloa le aoga o Ozempic®."
Novo Nordisk faʻamoemoe e faʻalauiloa le Ozempic® 2 mg i le Iunaite Setete i se taimi lata mai. Ozempic® 2 mg na faʻamaonia e Swiss Medic ia Setema 2021 sosoo ai ma le Health Canada ma le European Medicines Agency ia Ianuari 2022.
OA MEA E AVEA MAI LENEI TUSI:
- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2 mg dose of Ozempic® (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.
- In the Ozempic® SUSTAIN phase 3 clinical trial program, up to 73% of people with type 2 diabetes treated with Ozempic® 1 mg lowered their blood sugar and reached the American Diabetes Association target of <7%.
- “With Ozempic® now available in a variety of dosing strengths, we are optimistic we can help even more people living with type 2 diabetes who require more blood sugar control experience the benefits of Ozempic®.